SEC Company Response from Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354) — Jun 15, 2005
Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354)
Date: June 15, 2005 · CIK: 0001035354 · Accession: 0001104659-05-028335
AI Filing Summary & Sentiment
File numbers found in text: 333-125299
Letter
Securities and Exchange Commission Division of Corporation Finance Attention: Albert C. Lee Re: Senesco Technologies, Inc. Registration Statement on Form S-3 Filed on May 27, 2005 (File Number 333-125299)
Dear Mr. Lee:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Senesco Technologies, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the Company’s Registration Statement on Form S-3, File Number 333-125299, as amended, relating to the registration under the Securities Act of that number of shares of its common stock, $0.01 par value, as is set forth in such Registration Statement, for June 17, 2005, at 10:00 a.m. New York City time, or as soon as practicable thereafter.
This letter will confirm that the Company acknowledges that:
• should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to the delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
• the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
• the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
This letter will also confirm that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-captioned Registration Statement on Form S-3.
Very truly yours,
SENESCO TECHNOLOGIES,
INC.
Show Raw Text
CORRESP 1 filename1.htm [Senesco Letterhead] June 15, 2005 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Albert C. Lee Re: Senesco Technologies, Inc. Registration Statement on Form S-3 Filed on May 27, 2005 (File Number 333-125299) Dear Mr. Lee: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Senesco Technologies, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the Company’s Registration Statement on Form S-3, File Number 333-125299, as amended, relating to the registration under the Securities Act of that number of shares of its common stock, $0.01 par value, as is set forth in such Registration Statement, for June 17, 2005, at 10:00 a.m. New York City time, or as soon as practicable thereafter. This letter will confirm that the Company acknowledges that: • should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to the delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. This letter will also confirm that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-captioned Registration Statement on Form S-3. Very truly yours, SENESCO TECHNOLOGIES, INC. By: /s/ Bruce Galton Name: Bruce Galton Title: President and Chief Executive Officer